Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Fujifilm to Invest 300 Million Yen in Shimane Univ. Spinoff Regenerative Medicine Biotech
June 20, 2019
- Japan Approves 1st Avastin Biosimilar
June 19, 2019
- Eisai, Harvard Researchers Develop Novel Anticancer Agent Derived from Total Synthesis of Halichondrin
June 19, 2019
- Keytruda Momentum Unabated at ASCO, Snapshot of 5 Checkpoint Inhibitors
June 18, 2019
- 281 Apply for Torii’s Voluntary Redundancy Program
June 18, 2019
- Cold Agglutinin Disease Patients Have High Thromboembolism Event Risk: Sanofi Database Study
June 18, 2019
- VC Catalys Pacific Kicks Off in Japan in Partnership with Chugai, Eisai, Takeda, and More
June 18, 2019
- Daiichi Sankyo Espha Rolls Out AstraZeneca’s 3 Cancer AGs; Gx Onslaught for Lonasen, Urief
June 14, 2019
- Sumitomo Dainippon Tweaks Healios Cell Therapy Deal, Now Leads Japan Trials
June 14, 2019
- Nesp Biosame Priced at 62.8-69.2% of Originator
June 14, 2019
- Japanese Drug Makers Beefing Up China Biz amid Regulatory Tailwind
June 14, 2019
- Takeda to Propose Adding Shire Integration as Performance Objective for Execs’ Stock Compensation
June 14, 2019
- Shionogi Snaps Up Osaka Biotech after Hitting Joint Study Goals
June 14, 2019
- Takeda Founding Family Member Presses for Claw-Back Clause
June 13, 2019
- Growth of Japan Pharma Business Counts on Partnership with Foreign Biotechs: IQVIA Director
June 13, 2019
- Rakuten Medical Could File Photoimmunotherapy for Head and Neck Cancer in 2022; COO Says More Indications Eyed
June 12, 2019
- Taiho Sets Up Venture Capital to Spur Innovation in Japan
June 11, 2019
- Novartis’ Xolair Effective in Severe Cedar Pollen Allergy: Japan PIII
June 11, 2019
- JCR to Launch Japan PI/II for Temcell in Neonatal Hypoxic-Ischemic Encephalopathy
June 11, 2019
- Japan Ethical Drug Sales Surge 5.1% in April: Crecon
June 11, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…